Erratum: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings (PLoS ONE (2019) 14:9 (e0222658) DOI: 10.1371/journal.pone.0222658)

Abstract

Following the publication of this article [1] the authors received additional information that a correction [2] was published on an article [3] which the authors used for the real-world data (RWD) analysis. The authors were notified that a proportion of Medicare patients from the CMS database were unintentionally omitted from the original analysis [3]. The published corrected study [2] now incorporates the complete dataset. As a result, the authors have re-analyzed the RWD-based analysis based on the corrected dataset reported in [2]. This has resulted in numerical changes to the outcomes of RWD analyses, which are reflected in the updated versions of Fig 3, Tables 3, 4 and 5, and Supporting Information files provided with this notice. Statements in [1] that were affected by the re-analysis are listed and corrected in the table below titled, “Table 6. Text Corrections”. In this table, reference 12a is used to designate Lip et al. (2020) (listed as reference [2] in this Correction). The S3 Table legend in [1] cited reference 3 for Lip et al. (2018), which aligns with the reference number in S1 Appendix rather than the reference number in the article's main reference list. The legend has been updated, below, to cite publication years for the Lip et al. article (2018) and correction (2020) [2]. An Editorial Board member has reviewed the updates to the RWD-based analysis and determined that the conclusions of article [1] are upheld. (Figure Presented).